尼达尼布联合低分子肝素治疗对肺间质纤维化患者的影响

扫码查看

原文链接

万方数据
维普

中文摘要：目的:观察尼达尼布联合低分子肝素治疗对肺间质纤维化患者的影响。方法:选取2022年1月—2023年12月临泽县人民医院呼吸与危重症医学科收治的 80 例肺间质纤维化患者作为研究对象，按照随机数表法分为研究组和对照组，各 40 例。对照组采用低分子肝素治疗，研究组则在对照组基础上联用尼达尼布治疗，比较两组的临床疗效、炎症因子、肺功能指标、运动耐量、肺间质纤维化指标、动脉血气指标。结果:研究组治疗总有效率高于对照组，差异有统计学意义(P<0。05)。治疗后，观察组第 1 秒用力呼气容积(FEV1)、用力肺活量(FVC)、动脉血氧分压(PaO2)、动脉血氧饱和度(SaO2)、氧合指数(PaO2/FiO2)及 6 分钟步行试验(6MWT)评分均高于对照组，且Ⅲ型胶原(C-Ⅲ)、层粘连蛋白(LN)、透明质酸(HA)、动脉血二氧化碳分压(PaCO2)和白细胞介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)水平低于对照组，差异有统计学意义(P<0。05)。结论:达尼布与低分子肝素联合治疗肺间质纤维化效果较好，能够显著改善患者动脉血气指标和炎症刺激，提高肺功能，抑制肺间质纤维化，改善运动耐量，治疗实用性较高。

外文标题：Effect of Nintedanib Combined with Low Molecular Weight Heparin Treatment on Patients with Pulmonary Interstitial Fibrosis

外文摘要：Objective:To observe the effect of Nintedanib combined with Low Molecular Weight Heparin on patients with pulmonary interstitial fibrosis.Method:A total of 80 patients with pulmonary interstitial fibrosis admitted to the Department of Respiratory and Critical Care Medicine of Linze County People's Hospital from January 2022 to December 2023 were selected as the study objects,and they were divided into study group and control group according to random number table method,with 40 cases in each group.The control group was treated with Low Molecular Weight Heparin,and the study group was treated with Nintedanib on the basis of the control group.The clinical efficacy,inflammatory factors,pulmonary function indexes,exercise tolerance,pulmonary interstitial fibrosis indexes and arterial blood gas indexes of the two groups were compared.Result:The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC),arterial partial oxygen pressure(PaO2),arterial oxygen saturation(SaO2),oxygenation index(PaO2/FiO2)and 6 minutes walking test(6MWT)scores in the observation group were higher than those in the control group;the levels of type Ⅲ collagen(C-Ⅲ),laminin(LN),hyaluronic acid(HA),arterial partial pressure of carbon dioxide(PaCO2),interleukin-6(IL-6),procalcitonin(PCT)and C-reactive protein(CRP)were lower than those of control group,and the differences were statistically significant(P<0.05).Conclusion:The combination of Nintedanib and Low Molecular Weight Heparin in the treatment of pulmonary interstitial fibrosis has a good effect,which can significantly improve the arterial blood gas index and inflammatory stimulation of patients,improve lung function,inhibit pulmonary interstitial fibrosis,improve exercise tolerance,and have high therapeutic practicability.

外文关键词：

NintedanibLow Molecular Weight HeparinPulmonary interstitial fibrosisLung functionFibrosisArterial blood gas

作者：

朱正学

展开 >

作者单位：

临泽县人民医院甘肃临泽 734200

关键词：

尼达尼布低分子肝素肺间质纤维化肺功能纤维化动脉血气

出版年：

2024

DOI：